Characterization of Myeloproliferative Neoplasia With a Mutated IDH, SRSF2 or SF3B1 Allele (CARPEDIEM)
Active, not recruiting
- Conditions
- Myeloproliferative Disorders
- Registration Number
- NCT06481345
- Lead Sponsor
- University Hospital, Brest
- Brief Summary
Retrospective study assessing the impact of IDH1/2, SRSF2 or SF3B1 mutations on event free survival of MPN patients
- Detailed Description
Patients with a diagnosis of MPN and a mutation of IDH1/2, SRSF2 or SF3B1 will be included. Clinical and biological characterisation at diagnosis, as well as evlution will be recorded. Event free survival will be assessed in each group (event = thrombosis, transformation to mylofibrosis/acute leukemia, death).
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
- Patients with MPN diagnosis
- Mutation in IDH1/2, SRSF2 or SF3B1
Exclusion Criteria
- Unable to consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Event free survival 3 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Chu Brest
🇫🇷Brest, France